Pinc PeptideThe girly peptide research blog

Compare · updated 8 October 2026

BPC-157 vs GHK-Cu

The short answer

Neither is an approved drug, and neither has been shown to heal tendon, muscle or joint injuries in people345. GHK-Cu, a copper peptide also sold in skin creams, has been tested in controlled human trials only on skin and wounds, with mixed results678910. The five small published studies of BPC-157 that FDA found gave it to fewer than 100 people, for 2 weeks or less, and none of them looked at skin4111213. Both are sold in vials for injection, but we found no published human study of either one injected under the skin on its own, or of the two together12414.

At a glance

ComparedBPC-157GHK-Cu
Evidence tierB At least one controlled human trialB At least one controlled human trial
Does it work?For tendon and joint healing: UntestedFDA found no controlled human trial of it for tendons or joints; those claims rest on animal studies415. The only controlled trial in patients that FDA found, for a bowel disease, showed no clear benefit4.For firmer skin and fewer wrinkles (creams and serums): Mixed resultsIn small skin trials, a maker-funded serum reduced wrinkle volume more than a placebo serum10, but a laser-aftercare trial found no objective benefit8. We found no study that injected it alone in people14.
FDANot approved for any use4Cosmetic ingredient, not an approved drug56
US pharmaciesPharmacies may not make it16Pharmacies may make it for now, not injections161718
SportBanned at all times19Not named; unclear if a catch-all ban applies19202122
AustraliaPrescription only; illegal to hold without one23Not named; a prescription copper rule may apply23
Half-lifeAbout 15 minutes in rats and 5 minutes in dogs after an IV dose; unknown in humans24No human value found25
Taken asSubcutaneous injection (not used in any clinical study FDA found)
Oral capsules, tablets, gummies and sprays (sold as supplements and compounded products; a 2015 oral study and a 2025 gummy study have posted no results)
Nasal spray (no human data found)
Intramuscular injection (animal studies only)
Rectal enema (human studies reported 2002 to 2005)
Knee (intra-articular) injection (retrospective case series)
Injection into the bladder wall (single-arm pilot)
Intravenous infusion (2-person pilot)
Transdermal cream (proposed in a withdrawn compounding nomination; no human data found)		Topical creams, serums and gels (human trials)
Wound gels and dressings (human trials)
Subcutaneous injection (common in gray-market use; we found no human studies of GHK-Cu alone)
Scalp injection as one ingredient of hair-loss mixtures (two uncontrolled human studies)
Intraperitoneal injection and intranasal (animal studies only)
What it isA lab-made chain of 15 amino acids that FDA describes as a fragment of a protein first found in human gastric juice426.Copper bound to GHK, a peptide of 3 amino acids that occurs naturally in human blood; skin-care labels list it as copper tripeptide-12728.
How it might workUnknown: FDA says its targets have not been identified, and animal and cell studies suggest new blood-vessel growth and dampened inflammation429.Not settled: in rat wounds it increased the buildup of collagen, and lab and animal studies report new blood-vessel growth and anti-inflammatory effects303132.
Studied in people forFive small published studies: safety in healthy men, ulcerative colitis, knee pain, bladder pain, and IV safety in 2 people4111213.Skin and wounds in controlled trials: diabetic foot ulcers, leg ulcers, skin after laser treatment, facial wrinkles and sparse eyebrows; two uncontrolled hair-loss studies injected it as one ingredient of a mixture78910333435.
Best human evidenceOne randomized trial, in 53 people with ulcerative colitis and reported only as a meeting abstract, which found no statistically significant benefit4.Randomized wound trials: a gel closed a median 98.5% of the area of diabetic ulcers on the sole of the foot vs 60.8% with an inactive gel (the abstract gives no patient count), but a cream did no better than placebo on leg ulcers in the 86 patients who could be assessed79.
Biggest documented riskUnknown in people; in 28-day studies in rats and dogs it altered blood clotting and raised liver-related blood markers, and FDA found no study of its cancer risk436.Unknown for injection: we found no published human study of GHK-Cu injected on its own, and a 2026 review says injected products would need studies tracking copper build-up in the liver, nerves and kidneys1432.
Lab tests of gray-market vials92 of the latest 200 tests by Finnrick, an independent testing service, failed (27 May to 25 September 2026), and a bodega vial tested for WIRED held no BPC-1573738.43 of Finnrick’s latest 200 tests failed (23 June to 25 September 2026)39.

Which has better evidence for healing injuries?

A 2026 review for orthopedic and sports medicine doctors found that BPC-157’s reported benefits for tendon and muscle repair are largely unconfirmed in human trials, and that no clinical data support GHK-Cu’s use for muscle, bone or joint conditions3. For BPC-157, a 2025 systematic review found 36 relevant studies, 35 of them preclinical (done in animals or cells)15. In rats it sped the healing of cut Achilles tendons, but in a 2026 rat study its gains in healing scores were not statistically significant4041. Its only human data on joints come from a 2021 chart review: of 16 knee-pain patients reached by phone, 4 of whom had also received thymosin beta-4, 14 said the injections relieved their pain, and there was no control group11. As of 7 October 2026, a trial of BPC-157 after rotator cuff surgery was not yet recruiting and was not due to start until January 202742.

GHK-Cu’s human healing evidence comes from skin wounds79. In 1996 FDA cleared a GHK-Cu gel, Iamin, as a wound dressing, which is a device clearance, not a drug approval20. A 2026 systematic review of GHK-Cu used alone for cosmetic purposes, with searches to March 2026, included 20 studies, 18 of them preclinical and only 2 randomized trials31.

Has anyone tested BPC-157 and GHK-Cu together?

No. As of 7 October 2026, all 7 PubMed records found by a search for both names are reviews, and ClinicalTrials.gov lists no trial of the pair12.

Blends containing both have been sold: a Health Canada advisory of 24 December 2025 on products seized from a Vancouver gym listed ‘Glow’ vials labeled with BPC-157, TB-500 and GHK-Cu, and ‘Klow’ vials labeled with the same three plus KPV43.

A blend makes problems harder to trace: when a user’s skin and gums darkened after injecting a BPC-157 and TB-500 product, FDA could not tell which peptide was responsible4. Our BPC-157 vs TB-500 comparison covers the ‘Wolverine stack’ and other BPC-157 blends.

What are the side effects and risks of each?

FDA raises the same concern about injecting either one: peptides can clump and carry impurities that may trigger unwanted immune reactions417. Both also promote new blood-vessel growth in lab or animal studies2931. A 2026 review lists abnormal blood-vessel growth and cancer among the potential risks of unapproved peptides such as BPC-157, and another says GHK-Cu’s blood-vessel effect could be unwanted in tumors3244.

On 16 September 2026, Reuters reported that FDA’s adverse event data held 10 reports of serious adverse events involving BPC-157 since 2021, 8 of them in 2026; FDA notes that such a report does not confirm that the product caused the event45. A clinician interviewed by NPR said they see GHK-Cu self-injectors with injection-site irritation, infections and, in some cases, raised liver enzymes and copper levels; NPR noted it was unclear whether GHK-Cu or undisclosed substances or impurities were responsible6.

Copper adds its own risks with GHK-Cu: a researcher who studies GHK-Cu told NPR that overloading the body with too much copper is among the potential risks of injecting it, and copper is a recognized contact allergen in some people632.

How do regulators treat them?

In the US, BPC-157 and injectable GHK-Cu were both once in Category 2, FDA’s group of compounding substances that may present significant safety risks; their nominations were withdrawn, and as of 1 October 2026 FDA’s safety-risk page listed both as ‘nominated but withdrawn’17. FDA’s compounding advisers voted 8-6, with 1 abstention, on 23 July 2026 in favor of letting pharmacies compound BPC-157, against FDA staff advice446. The vote is advisory, and as of 30 September 2026 FDA had not proposed a rule or changed BPC-157’s status164647.

GHK-Cu’s status changed twice in 2026: on 22 April 2026, after its nominations were withdrawn, FDA dropped non-injectable GHK-Cu from Category 1, the group FDA lets pharmacies use while it decides on them16. After one nominator clarified on 5 May 2026 that it had withdrawn only the injectable route, FDA added the non-injectable forms back to Category 116. FDA intends to consult its advisers on GHK-Cu before the end of February 202716.

Health Canada has listed both among unauthorized injectable peptides it has seized, and in May 2026 a Canadian supplier recalled GHK-Cu and BPC-157 powders from compounding and community pharmacies as unauthorized active ingredients4849. On 1 April 2026, US prosecutors announced the indictment of a Utah physician on charges of receiving misbranded drugs from China, including BPC-157 and GHK-Cu, and selling them to patients; an indictment is only an allegation50.

Questions people ask

What is the difference between BPC-157 and GHK-Cu?

BPC-157 is a lab-made peptide of 15 amino acids described as a fragment of a protein from human gastric juice, while GHK-Cu is copper bound to GHK, a peptide of 3 amino acids that occurs naturally in human blood427. GHK-Cu is also a skin-care ingredient tested in small skin and wound trials, while BPC-157’s few human studies looked at a bowel disease, knee pain and bladder pain46111231.

Is BPC-157 or GHK-Cu better for skin?

Only GHK-Cu has been tested on skin in people: in a maker-funded trial in 20 women, wrinkle volume fell 24.1% on the GHK-Cu side of the face vs 15.0% on the placebo side, and in 18 adults the eyebrow treated with a GHK-Cu serum gained hairs while the placebo side did not change significantly1033. After laser skin treatment, though, it gave no objective benefit8. FDA’s review lists no human study of BPC-157 for skin, and we found none of either one injected for skin414.

Which is better for healing injuries, BPC-157 or GHK-Cu?

Neither: human studies have not shown that either one heals tendon, muscle or joint injuries3. BPC-157 has been tested on tendon injuries mainly in rats, with mixed results, while GHK-Cu’s human healing data come from skin wounds, where a gel helped diabetic foot ulcers but a cream did not help leg ulcers794041.

Can you take BPC-157 and GHK-Cu together?

No published or registered study has tested the combination, so its effects and risks are unknown12. On its own, each carries a possible risk of immune reactions when injected, according to FDA417. Blends containing both have been seized in Canada, and when a blend causes a reaction it can be impossible to tell which ingredient was responsible, as FDA found with a BPC-157 and TB-500 product443.

Is GHK-Cu safer than BPC-157?

As skin care, GHK-Cu has the longer record: copper peptide creams and serums have been sold for decades and studied in human trials6. Injected under the skin, neither has published human data showing it is safe, and FDA flags possible immune reactions for both4617.

Go deeper

Sources

  1. 1PubMed search: BPC-157 AND GHK (7 results, all reviews) National Library of Medicine (PubMed), accessed 7 Oct 2026. pubmed.ncbi.nlm.nih.gov
  2. 2ClinicalTrials.gov search for ‘BPC-157 AND GHK’ (0 studies) ClinicalTrials.gov, accessed 7 Oct 2026. clinicaltrials.gov
  3. 3Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians The American Journal of Sports Medicine, Jan 2026. pubmed.ncbi.nlm.nih.gov
  4. 4FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: BPC-157-related bulk drug substances U.S. Food and Drug Administration, 11 May 2026. fda.gov
  5. 5Drugs@FDA search for products containing prezatide (openFDA drugsfda endpoint; no matches) U.S. Food and Drug Administration (openFDA), accessed 1 Oct 2026. api.fda.gov · data query
  6. 6The copper peptide trend has gone from creams to injections — ahead of the science NPR, 7 Sep 2026. npr.org
  7. 7Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper Wound Repair and Regeneration, Oct 1994. pubmed.ncbi.nlm.nih.gov
  8. 8Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin Archives of Facial Plastic Surgery, Jul 2006. pubmed.ncbi.nlm.nih.gov
  9. 9A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers Journal of Vascular Surgery, Aug 1992. pubmed.ncbi.nlm.nih.gov
  10. 10Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters Journal of Aging Science, 22 Dec 2016. doi.org
  11. 11Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Alternative Therapies in Health and Medicine, Jul 2021. pubmed.ncbi.nlm.nih.gov
  12. 12Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study Alternative Therapies in Health and Medicine, Oct 2024. pubmed.ncbi.nlm.nih.gov
  13. 13Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study Alternative Therapies in Health and Medicine, Sep 2025. pubmed.ncbi.nlm.nih.gov
  14. 14PubMed search: GHK-Cu or copper peptide names with injection terms (28 results; two injected people, each with a copper peptide as one ingredient of a hair-loss mixture) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
  15. 15Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review HSS Journal, Nov 2025. pubmed.ncbi.nlm.nih.gov
  16. 16Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
  17. 17Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
  18. 18Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration, 14 May 2026. fda.gov
  19. 19World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
  20. 20510(k) Premarket Notification K953853: Iamin Gel Wound Dressing (Procyte Corp.) U.S. Food and Drug Administration, 5 Feb 1996. accessdata.fda.gov
  21. 21World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  22. 22Summary of Major Modifications and Explanatory Notes: 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  23. 23Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
  24. 24Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs Frontiers in Pharmacology, 2022. pubmed.ncbi.nlm.nih.gov
  25. 25Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization Journal of Chromatography B, 25 Apr 1997. pubmed.ncbi.nlm.nih.gov
  26. 26A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC Journal of Physiology, Paris, 1993. pubmed.ncbi.nlm.nih.gov
  27. 27Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells Nature, 25 Dec 1980. pubmed.ncbi.nlm.nih.gov
  28. 28PREZATIDE COPPER (UNII 6BJQ43T1I9) substance record FDA Global Substance Registration System (GSRS), accessed 1 Oct 2026. precision.fda.gov
  29. 29Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation Journal of Molecular Medicine, Mar 2017. pubmed.ncbi.nlm.nih.gov
  30. 30In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds The Journal of Clinical Investigation, Nov 1993. pubmed.ncbi.nlm.nih.gov
  31. 31The Regenerative Potential of GHK-Cu in Aesthetic Medicine Aesthetic Surgery Journal, 20 Aug 2026. pubmed.ncbi.nlm.nih.gov
  32. 32GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap Pharmaceutics, 27 Aug 2026. pmc.ncbi.nlm.nih.gov
  33. 33The efficacy of 2% copper peptide (GHK-Cu) serum for eyebrow hypotrichosis: a randomized, double-blind, vehicle-controlled, split-face comparative study Procedia of Multidisciplinary Research, 22 May 2026. so09.tci-thaijo.org
  34. 34Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study Journal of Cosmetic and Laser Therapy, Oct 2018. pubmed.ncbi.nlm.nih.gov
  35. 35Androgenetic Alopecia Treatment in Asian Men The Journal of Clinical and Aesthetic Dermatology, Jul 2018. pubmed.ncbi.nlm.nih.gov
  36. 36Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds Regulatory Toxicology and Pharmacology, Jul 2020. pubmed.ncbi.nlm.nih.gov
  37. 37BPC-157 Safety Testing Results & Vendor Ratings Finnrick, 29 Sep 2026. finnrick.com
  38. 38Those Viral Bodega Peptides Aren’t Actually Peptides WIRED, 15 Sep 2026. wired.com
  39. 39GHK-Cu: vendor test results Finnrick, 25 Sep 2026. finnrick.com
  40. 40Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth Journal of Orthopaedic Research, Nov 2003. pubmed.ncbi.nlm.nih.gov
  41. 41Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Joint Diseases and Related Surgery, 23 Jul 2026. pubmed.ncbi.nlm.nih.gov
  42. 42Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (NCT07803250) ClinicalTrials.gov, 3 Sep 2026. clinicaltrials.gov
  43. 43Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks (RA-81403) Health Canada, 24 Dec 2025. recalls-rappels.canada.ca
  44. 44Dangers of Injectable Peptides and Other Unregulated “Biohacking” Drugs Missouri Medicine, 2026. pubmed.ncbi.nlm.nih.gov
  45. 45Use of experimental ‘Wolverine’ peptide backed by RFK Jr is on the rise, study finds The Independent (Reuters), 16 Sep 2026. independent.co.uk
  46. 46PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 24 Jul 2026. thefdalawblog.com
  47. 47July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
  48. 48Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874) Health Canada, 9 Apr 2026. recalls-rappels.canada.ca
  49. 49GHK-Cu & BPC-157 powder: Unauthorized active pharmaceutical ingredients (RA-82047) Health Canada, 7 May 2026. recalls-rappels.canada.ca
  50. 50Utah Licensed Osteopathic Physician Indicted for Allegedly Receiving Misbranded Drugs from China and Selling them to Patients U.S. Attorney’s Office, District of Utah, 1 Apr 2026. justice.gov

Not medical advice. Neither compound is recommended here. How we grade evidence · Report an error.